Outsourcing Production Is First Step In Staving Off GMP Consent Decrees
This article was originally published in The Tan Sheet
Executive Summary
Outsourcing manufacturing as soon as GMP violations are identified can help firms avoid FDA enforcement, making available extra resources to assess and enact remediation, experts advise. Open, company-wide communication and celebrating successes while remediating under a consent decree also are key, too.
You may also be interested in...
J&J Prioritizes OTC Return With McNeil Remediation End In Sight
Johnson & Johnson CEO Alex Gorsky says bringing recalled OTCs such as Tylenol and Motrin products back to market is the firm’s “clear number one priority” in the near term. J&J also has a timetable for completing its responsibilities under a consent decree with FDA in place since 2011.
J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
Ensuring Leading Position For GSK Consumer Products Touted In Management Shift
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.